Massachusetts is the home to our growing UCB US Research and Development (R&D) hub. We have more than 125 UCB employees across our facilities in Bedford and Cambridge, in addition to our field-based employees across the state.
We believe ground-breaking research best flourishes in innovative ecosystems. This is why UCB’s presence in Massachusetts is critical for our work to further scientific understanding and uncover new discoveries. We’re exploring novel areas of research, testing hypotheses on what drives disease progression and can modify disease and researching new ways to better connect science to the needs of patients.
At our 94,000 square feet of lab and office facilities in Cambridge and Bedford, our scientists are working on new platforms and projects we aim that one day will lead to cures. Building on UCB’s existing global capabilities, our team is focused on developing capabilities in areas including targeted protein degradation, protein biochemistry, and structural biology and leveraging a proprietary peptide chemistry platform as ways to discover new medicines for treating patient populations with severe neurodegenerative and immunological diseases, including those that are rare. More info on UCB in rare disease.
UCB’s External Innovation and Ventures teams also have a presence in Cambridge to ensure we are keeping connected with latest opportunities and exploring new areas for partnership, collaboration, and investment. UCB Ventures is actively investing in emerging biotech.
Oct 26, 2021
Posted by UCB